

**Tabla 1**Tabla de pruebas identificativas para los 4 aislamientos de *Candida*

| Aislamientos | API 32C®       | API 32C® (repetición)  | VITEK® MS MALDI-TOF    | ITS secuenciación      |
|--------------|----------------|------------------------|------------------------|------------------------|
| Primero      | <i>C. sake</i> | <i>C. parapsilosis</i> | <i>C. parapsilosis</i> | <i>C. parapsilosis</i> |
| Segundo      | <i>C. sake</i> | <i>C. parapsilosis</i> | <i>C. parapsilosis</i> | <i>C. parapsilosis</i> |
| Tercero      | <i>C. sake</i> | <i>C. sake</i>         | <i>Pichia farinosa</i> | <i>C. metapsilosis</i> |
| Cuarto       | <i>C. sake</i> | <i>C. sake</i>         | <i>C. haemulonii</i>   | <i>C. haemulonii</i>   |

compararon con aquellas depositadas en la base de datos del GenBank mediante BLAST.

Adicionalmente, se estudió la capacidad del sistema VITEK® MS™ -basado en MALDI-TOF®- (bioMérieux)<sup>7</sup> para la identificación de los 4 aislamientos, siguiendo la metodología recomendada por el fabricante.

La identificación molecular demostró que los aislamientos correspondían a *Candida parapsilosis* ( $n=2$ ), *Candida metapsilosis* ( $n=1$ ) y *Candida haemulonii* ( $n=1$ ). El sistema VITEK® MS identificó correctamente las 2 cepas de *C. parapsilosis* y la de *C. haemulonii*, pero identificó erróneamente *C. metapsilosis* como *Pichia farinosa*. Este sistema no incluye las especies del grupo «psilos» en la base de datos de MS-ID v1 (bioMérieux).

Nuestros resultados muestran que la identificación de *C. sake* con API 32C® debería confirmarse con un método molecular. La literatura refiere hasta un 86% de eficacia para especies de *Candida* frecuentes y de un 85% en las infrecuentes<sup>4</sup>, pero el auténtico problema de esta prueba es la variabilidad entre observadores y la necesidad de una cierta experiencia a la hora de interpretar las galerías.

Es conveniente evaluar el sistema MALDI-TOF® VITEK® MS para comprobar su posible utilidad como método rápido alternativo, de la misma manera que sería necesario incrementar su base de datos. Algunos trabajos presentan excelentes resultados respecto a la identificación de levaduras por el sistema MALDI-TOF® con rangos de eficacia del 95 al 100%<sup>1,3,5</sup>.

## Financiación

Ninguna.

## Conflictos de intereses

Ninguno.

## Paracoccidioidomycosis and HIV coinfection presenting severe disease even with CD4<sup>+</sup> cells in the normal range

## Paracoccidioidomycosis grave en un paciente coinfecado por el VIH con valores normales de linfocitos CD4<sup>+</sup>

Dear Editors:

Paracoccidioidomycosis is a systemic mycosis caused by *Paracoccidioides brasiliensis*, and it's endemic in many countries of South America.<sup>10</sup> It has been uncommonly reported in AIDS patients until last few years, when it has been more frequently described.<sup>3,8,9,11</sup> Recently, Morejón et al. showed that paracoccidioidomycosis and HIV-infected patients ( $n=53$ ) presented CD4<sup>+</sup> count <200 cells/ $\mu$ L in 83.7%, lymphadenomegaly in 80%, cutaneous lesions in 66.7% and hepatomegaly in 64.2% of studied cases. Moreover, 80% of patients presented a HIV viral load of >30,000 copies/mL of plasma.<sup>5</sup> These data suggest that, severe paracoccidioidomycosis in HIV/aids patients is an related to pronounced immunosuppression.

## Agradecimientos

Hospital Universitario Marqués de Valdecilla.

## Bibliografía

- Cherkaoui A, Hibbs J, Emonet S, Tangomo M, Girard M, Francois P, et al. Comparison of two MALDI-TOF mass spectrometry methods with conventional phenotypic identification for routine identification of bacteria to the species level. *J Clin Microbiol*. 2010;48:1169–75.
- Gutierrez J, Martin E, Lozano C, Coronilla J, Nogales C. Evaluation of the ATB 32C, automicrobiotic system and API 20C using clinical yeast isolates. *Ann Biol Clin (Paris)*. 1994;52:443–6.
- Marklein G, Josten M, Klanke U, Müller E, Horré R, Maier T, et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates. *J Clin Microbiol*. 2009;47: 2912–7.
- Ramani R, Gromadzki S, Pincus DH, Salkin IF, Chaturvedi V. Efficacy of API 20C and ID 32C systems for identification of common and rare clinical yeast isolates. *J Clin Microbiol*. 1998;36:3396–8.
- Van Veen SQ, Claas EC, Kuijper EJ. High-throughput identification of bacteria and yeast by matrix-assisted laser desorption ionization-time of flight mass spectrometry in conventional medical microbiology laboratories. *J Clin Microbiol*. 2010;48:900–7.
- White TJ, Bruns T, Lee S, Taylor J. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. En: Innis A, Gelfand DH, Sninsky JJ, White TJ, editores. *PCR protocols: A guide to methods and applications*. San Diego, CA: Academic Press; 1990. p. 315–22.
- Yaman G, Akyar I, Can S. Evaluation of the MALDI TOF-MS method for identification of *Candida* strains isolated from blood cultures. *Diagn Microbiol Infect Dis*. 2012;73:65–7.

Carlos Ruiz de Alegría Puig<sup>a,\*</sup>, Carlos Armiñanzas<sup>b</sup>, Jesús Agüero Balbín<sup>a</sup>, Luis Martínez Martínez<sup>a</sup> y María Carmen Fariñas<sup>b</sup>

<sup>a</sup> Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla-Instituto de Formación en Investigación Marqués de Valdecilla, Universidad de Cantabria, Santander, España

<sup>b</sup> Unidad de Enfermedades Infecciosas, Hospital Universitario Marqués de Valdecilla-Instituto de Formación en Investigación Marqués de Valdecilla, Universidad de Cantabria, Santander, España

\* Autor para correspondencia.

Correo electrónico: carlosrdap@hotmail.com  
(C. Ruiz de Alegría Puig).

<http://dx.doi.org/10.1016/j.riam.2013.07.001>

However, coinfected patient can present severe and disseminated disease even with CD4<sup>+</sup> cell count in the normal range, as observed in this case report.

We report the case of a 21-year-old male patient from an urban area of São Paulo state, Brazil, who was referred with a four-month history of fever, weight loss, lymphadenomegaly and cutaneous lesions. He had been an inmate in a state prison, and had inhaled illicit drugs but denied previous medical problems. His clinical presentation was remarkable due to multiple erythematous, infiltrated and ulcerated skin lesions on his face, trunk and limbs (Figs. 1 and 2). He also presented cervical, axillary and inguinal lymphadenomegaly plus hepatomegaly. Biopsy samples from skin lesions and cervical lymph nodes showed diagnostic structures of *P. brasiliensis* (Fig. 3). Nested-PCR and culture in Mycosel® agar from skin tissue sample were also positive for *P. brasiliensis*. Chest X-ray and computerized tomography (CT) showed normal to discrete interstitial pulmonary infiltration. Abdominal CT revealed diffuse augmentation of liver and spleen and retroperitoneal lymphadenomegaly. A suspected HIV infection was confirmed by


positive serology (ELISA and Western-blot tests). Additional laboratory studies showed CD4<sup>+</sup> = 875 cells/ $\mu$ L; viral load >30,000 copies and double immunodiffusion test for anti-*P. brasiliensis* antigen with positive results (IDD = 1/16). Hematological study was normal with an erythrocyte sedimentation rate of 42 mm/h. Testing of HBV, HCV and HTLV-I was negative.



**Fig. 1.** Paracoccidioidomycosis: papule, nodule, infiltrated and ulcerative lesion on frontal region.



**Fig. 2.** Paracoccidioidomycosis: multiple infiltrated and ulcerated lesions with satellites on the back.



**Fig. 3.** Paracoccidioidomycosis: typical aspect of *P. brasiliensis* on the dermis (silver methenamine  $\times 1000$ ).

Treatment was performed with amphotericin B, total dose = 1960 mg with clinical cure, followed by trimethoprim-sulfamethoxazole 320 + 1600 mg/daily. HAART therapy was not prescribed at that moment and patient did not return for the follow-up.

This reported case is very useful to demonstrate some aspects related to paracoccidioidomycosis and HIV coinfection: although the expected clinical profile of paracoccidioidomycosis in patients bearing the age of this particular case is to present lymphadenomegaly and skin lesion, the exuberance of this clinical presentation, particularly the magnitude of lymphonodes augmentation and number & aspect of skin lesions draw our attention to possible subjacent immunosuppression, in this case an unnoted HIV-infection. It has also been suggested that urban and young patients with severe paracoccidioidomycosis might be routinely screened for HIV infection. Also important is the fact that patients with paracoccidioidomycosis and HIV despite clinical severity can present discrete pulmonary involvement or no detectable involvement at all and, that amphotericin B deoxycholate is still the first choice in severe paracoccidioidomycosis despite its side effects.<sup>1,2,4,7</sup>

As the HIV infection is spreading to the interior of many countries in South and Central America, the possibility of HIV associated to endemic diseases prevalent in such countries must be considered in our clinical reasoning.<sup>6</sup>

## Bibliografía

1. Bellissimo-Rodrigues F, Vitali LH, Martinez R. Serological diagnosis of paracoccidioidomycosis in HIV-coinfected patients. Mem Inst Oswaldo Cruz. 2010;105:904–7.
2. Benard G, Duarte AJS. Paracoccidioidomycosis: a model for evaluation of the effects of human immunodeficiency virus on the natural history of endemic tropical diseases. Clin Infect Dis. 2000;31:1032–9.
3. Marques SA, Robles AM, Tortorano AM, Tuculet R, Negroni R, Mendes RP. Mycosis associated with AIDS in the third world. Med Mycol. 2000;38 Suppl. 1: 269–79.
4. Marques SA, Camargo RMP, Abbade LPF, Fortaleza CMCB, Marques MEA. Paracoccidioidomycosis: an unusual presentation in a young girl disclosing an unnoted HIV-infection. Med Mycol. 2010;48:182–7.
5. Morejón KML, Machado AA, Martinez R. Paracoccidioidomycosis in patients infected with and not infected with human immunodeficiency virus: a case control study. Am J Trop Med Hyg. 2009;80:359–66.
6. Navascués A, Rodríguez I, Repáraz J, Salvo S, Gil-Setas A, Martínez Peñuela JM. Imported histoplasmosis in Navarra: presentation of four cases. Rev Iberoam Microl. 2011;28:194–7.
7. Nogueira LMC, Santos M, Ferreira LCL, Talhari C, Rodrigues RB, Talhari S. AIDS-associated paracoccidioidomycosis in a patient with a CD4<sup>+</sup> T-cell count of 4 cells/mm<sup>3</sup>. An Bras Dermatol. 2011;86 Suppl. 1:129–32.
8. Paniago AM, Freitas AC, Aguiar ESA, Aguilar JIA, Cunha RV, Castro AR, et al. Paracoccidioidomycosis in patients with human immunodeficiency virus: a review of 12 cases observed in an endemic region of Brazil. J Infect. 2005;51: 248–52.
9. Silva-Vergara ML, Teixeira AC, Curi VGM, Costa Junior R, Vanunce WM, Carmo Silva MR. Paracoccidioidomycosis associated with human immunodeficiency virus infection. Report of 10 cases. Med Mycol. 2003;41: 259–63.
10. Wanke B, Londero AT. Epidemiology and paracoccidioidomycosis infection. In: Franco M, Lacaz CS, Restrepo-Moreno A, Del Negro G, editors. Paracoccidioidomycosis. Boca Raton: CRC Press; 1994. p. 109–17.
11. Zaputovich FA, Cardozo L, Di Martino B, Valdovinos G, Masi MR, Knopfelmacher O, et al. Paracoccidioidomycosis en paciente HIV+. Rev Esp Patol. 2008;41:150–3.

Silvio Alencar Marques <sup>a,\*</sup>, Liara Petrechen <sup>a</sup>, Aline C. Kakuda <sup>a</sup>, Maria Paula V Chiossi <sup>b</sup>, Mariangela EA Marques <sup>a</sup>

<sup>a</sup> Faculdade de Medicina de Botucatu, São Paulo, Brazil  
<sup>b</sup> Chiossi Private Office, São Paulo, Brazil

\* Corresponding author.

E-mail address: smarques@fmb.unesp.br (S. Alencar Marques).